NASDAQ$TRML
Tourmaline Bio Inc · Q3 2025 earnings
Q3 2025 earnings · · Before market open · Investor relations
Reports awaiting report
Tourmaline Bio hasn't published Q3 2025 actuals yet. The tiles below frame what to compare against; sections further down are historical context only.
Most recent report Q2 2025
- Revenue
- $0.00
- EPS
- -$0.90
Year-ago · Q3 2024 Q3 2024
- Revenue
- $87K
- EPS
- -$0.78
FY2025 consensus Analyst consensus
- Revenue
- $8.57M
- EPS
- -$3.53
Revenue & EPS history
Tourmaline Bio · Revenue · Quarterly
$0
Q2 2025-100%vs Q2 2024
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 6 quarterly earnings reports
+0.7%
Avg return
Earnings day
-5.0%
Avg return
5 days after
+13.7%
Avg return
30 days after
59%
10 / 17 earnings
Positive
+11.6%
Q4 2023
Best reaction
-9.7%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | — | — | — | |
| Q2 2025 | +3.8% | +3.1% | +122.3% | |
| Q1 2025 | +4.6% | +9.9% | +26.5% | |
| Q4 2024 | -2.8% | -4.8% | -1.4% | |
| Q3 2024 | +5.0% | -4.9% | -5.6% | |
| Q2 2024 | +2.0% | +4.6% | +12.2% | |
| Q1 2024 | -0.6% | -4.8% | +2.6% | |
| Q4 2023 | +11.6% | -38.1% | -60.9% | |
| Q3 2023 | -1.2% | — | — | |
| Q2 2023 | +1.3% | — | — | |
| Q1 2023 | -8.0% | — | — | |
| Q4 2022 | +2.8% | — | — | |
| Q3 2022 | +7.0% | — | — | |
| Q2 2022 | -9.7% | — | — | |
| Q1 2022 | +3.1% | — | — | |
| Q4 2021 | +4.6% | — | — | |
| Q3 2021 | -7.0% | — | — | |
| Q2 2021 | -5.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro